Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma
Case Reports in Rheumatology · 2012
DOI: 10.1155/2012/208606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Rheumatology, 2012. Verfasst von D Graceffa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.
Autor:innen und Institutionen
- Centre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.
Zitieren
APA
Graceffa, D., Maiani, E., Pace, A., Solivetti, F. M., Elia, F., De Mutiis, C., & Bonifati, C. (2012). Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. Case Reports in Rheumatology. https://doi.org/10.1155/2012/208606
Vancouver
Graceffa D, Maiani E, Pace A, Solivetti FM, Elia F, De Mutiis C, et al. Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. Case Reports in Rheumatology. 2012. doi:10.1155/2012/208606
BibTeX
@article{Graceffa2012,
author = {Graceffa, D and Maiani, E and Pace, A and Solivetti, F M and Elia, F and De Mutiis, C and Bonifati, C},
title = {Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma},
journal = {Case Reports in Rheumatology},
year = {2012},
doi = {10.1155/2012/208606}
}
EUVIMED